Skip to main content

Advertisement

Table 1 Baseline characteristics of 103 patients

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic Frequency %
  Median (years) 54 (range, 22-78)
Age <60 63 61.2
  ≥ 60 40 38.8
Sex Male 58 56.3
  Female 45 43.7
  Absent 92 89.3
Carcinoid symptom Present 5 4.9
  Unavailable 6 5.8
  Pancreas 26 25.2
  GI tract 27 26.2
     Foregut 11 10.7
     Midgut 1 1.0
Origin    Hindgut 15 14.6
  Lung 2 1.9
  Etc.* 28 27.2
  Unknown 20 19.4
Initial metastatic site Liver 50 74.6
  Bone 12 17.9
  Lung 12 17.9
  Brain 3 4.5
  Lymph node 20 29.9
  Etc. 10 14.9
Recurrent site Liver 15 41.7
  Bone 16 44.4
  Lung 1 2.8
  Brain 1 2.8
  Lymph node 15 41.7
  Etc. 3 8.3
  Local 21 21.4
Prior stage Regional 15 14.6
  Distant 67 65.0
  1 34 33.0
  2 1 1.0
Grade 3 15 14.6
  Large 9 8.7
  Small 7 6.8
  Unclassified 25 24.3
  Unavailable 12 11.7
   Median (range) 23.0 (2.6-1324.6)
  24-hour urine 5-HIAA (μmol/day) <31.4 (reference range) 15 71.4
Biomarkers   ≥ 31.4 6 28.6
   Median (range) 1.6 (0.4-23.1)
  Serum NSE (nmol/l) <1.0 (reference range) 12 36.4
   ≥ 1.0 21 63.6
  1. GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase
  2. * The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)
  3. Available data: 21
  4. Available data: 33